

Table S3. Number of viral isolates from ART suppressed individuals with and without treatment interruption

Virus	Subjects ¹	Gender ²	Years on ART before ATI ³	Sample time point	Viral load (copies/μl)	CD4 count (cells/μl)	Sample ⁴	Number of Limiting dilution virus Isolates ⁵	Study Number	References
VOA	B199	M	4	second leukapheresis	<20	200	QVOA Supernatant	1	MNU-0628	Lorenzi et al., 2016
VOA	B106	M	7	first and second leukapheresis	<20	390	QVOA Supernatant	2		
VOA	9242	M	2	during ATI (12 weeks) before rebound	<20	967	QVOA Supernatant	2	NCT02825797	Mendoza et al., 2018
VOA	9243	M	5	during ATI (12 weeks) before rebound	<20	545	QVOA Supernatant	1		
VOA	9244	M	5	2 weeks pre ATI	<20	796	QVOA Supernatant	4		
VOA	9244	M	5	during ATI (12 weeks) before rebound	<20	796	QVOA Supernatant	2		
VOA	9241	M	5	during ATI (12 weeks) before rebound	<20	709	QVOA Supernatant	1		
VOA	9241	M	5	2 weeks pre ATI	<20		QVOA Supernatant	4		
Rebound	9242	M	2	16 weeks post ATI	65,520	450	Plasma	5		
Rebound	9243	M	5	21 weeks post ATI	10,110	350	Plasma	1		
Rebound	9244	M	5	22 weeks post ATI	120,330	730	Plasma	5		
Rebound	9241	M	5	22 weeks post ATI	13,250	500	Plasma	1		
VOA	A06	M	>3.6	2.5 weeks pre ATI	<50	>470	QVOA Supernatant and cryopreserved PBMC	6	NCT02463227	Bar et al., 2016; Salantes et al., 2018
VOA	A06	M	>3.6	10.5 months post ATI	<50		QVOA Supernatant	3		
VOA	A08	M	>3.6	4 weeks pre ATI	<50	>470	QVOA Supernatant	4		
VOA	A08	M	>3.6	11 months post ATI	<50		QVOA Supernatant and cryopreserved PBMC	16		
VOA	A09	M	>3.6	1 week pre ATI	<50	>470	QVOA Supernatant	4		
VOA	A09	M	>3.6	12 months post ATI	<50		QVOA Supernatant	2		
Rebound	A09	M	>3.6	3 weeks post ATI	2,330	>350	Plasma	8		
Rebound	A08	M	>3.6	5 weeks post ATI	20,000	>350	Plasma	17		
Rebound	S22	M	8	during 2nd ATI	750,000	449	Plasma	5	NCT00051818	Papasavvas et al., 2004
Rebound	S23	M	5	during 2nd ATI	556,372	351	Plasma	2		
Rebound	S30	M	5	during 3rd ATI	517,473	467	Plasma	4		
Rebound	004	M	>1	4 weeks post ATI (week 12 of study)	33,812	794	Plasma	4	NCT02227277	Azzoni et al, 2020
Rebound	030	M	>1	4 weeks post ATI (week 12 of study)	18,056	377	Plasma	4		
Rebound	044	F	>1	4 weeks post ATI (week 12 of study)	20,171	496	Plasma	4		
Rebound	601	M	20	5 weeks post ATI (week 29 of study)	112,160	707	Plasma	6	NCT02588586	Cohen et al., 2018

¹All subjects were recruited in the US and had subtype B infections, except for subject A09 who also had a subtype A strain (only subtype B viruses were isolated)

²M, male; F, female.

³ATI, analytical treatment interruption

⁴QVOA, quantitative viral outgrowth assay

⁵Viral isolates were confirmed by sequence analysis to be single virion-derived (Genbank accession number are shown in Table S X)